Diagnosis and management of aspergillosis in the Netherlands: a national survey

Lestrade, P.P.A.; Meis, J.F.; Arends, J.P.; Beek, M.T. van der; Brauwer, E. de; Dijk, K. van; ... ; Verweij, P.E. (2016)

Article / Letter to editor

A survey of diagnosis and treatment of invasive aspergillosis was conducted in eight University Medical Centers (UMCs) and eight non-academic teaching hospitals in the Netherlands. Against a background of emerging azole resistance in Aspergillus fumigatus routine resistance screening of clinical isolates was performed primarily in the UMCs. Azole resistance rates at the hospital level varied between 5% and 10%, although rates up to 30% were reported in high-risk wards. Voriconazole remained first choice for invasive aspergillosis in 13 out of 16 hospitals. In documented azole resistance 14 out of 16 centres treated patients with liposomal amphotericin B.

• Aspergillosis
• azole resistance
• treatment

• All authors: Lestrade, P.P.A.; Meis, J.F.; Arends, J.P.; Beek, M.T. van der; Brauwer, E. de; Dijk, K. van; Greeff, S.C. de; Haas, P.J.; Hodiamont, C.J.; Kuijper, E.J.; Leenstra, T.; Muller, A.E.; Lashof, A.M.L.O.; Rijnders, B.J.; Roelofsen, E.; Rozemeijer, W.; Tersmette, M.; Terveer, E.M.; Verduin, C.M.; Wolfhagen, M.J.H.M.; Melchers, W.J.G.; Verweij, P.E.
• Date: 2016-02-01
• Journal: Mycoses
• Volume: 59
• Issue: 2
• Pages: 101 - 107
• DOI: doi:10.1111/myc.12440